Ziopharm Oncology, Solasia deal

Ziopharm and Solasia amended a 2011 deal granting Solasia exclusive rights to develop and commercialize IV and oral darinaparsin ( ZIO-101) in 13 Asia-Pacific territories. Under the amended deal, Solasia now has exclusive, worldwide rights to develop and commercialize darinaparsin and related organic arsenic molecules in both IV and oral forms for all human indications. Ziopharm will be eligible to receive up to $72.2 million in milestones, plus double-digit royalties and a percentage of any sublicense revenues generated by Solasia, which will be responsible for development, manufacturing and commercialization. ...